BIOCRYST PHARMACEUTICALS, INC. Revenue from Contract with Customer, Including Assessed Tax
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Revenue from Contract with Customer, Including Assessed Tax of $218.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $218.25M, a 33.61% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $156.41M, a 7.48% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $406.56M, a 209.09% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $159.40M, a 36.14% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $874.84M, a 94.10% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $450.71M, a 36.00% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $331.41M, a 22.37% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. revenue from contract with customer, including assessed tax for fiscal 2022 was $270.83M, a 72.31% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $218.25M 10-Q · filed 2026-08-05 | $374.66M 10-Q · filed 2026-08-05 | $781.22M derived: sum of 3 quarters · filed 2026-08-05 | $940.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $156.41M 10-Q · filed 2026-05-06 | $562.97M derived: sum of 2 quarters · filed 2026-05-06 | $722.36M derived: sum of 3 quarters · filed 2026-05-06 | $885.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $406.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $565.95M derived: sum of 2 quarters · filed 2026-02-26 | $729.30M derived: sum of 3 quarters · filed 2026-08-05 | $874.84M 10-K · filed 2026-02-26 |
| 2025-09-30 | $159.40M 10-Q · filed 2025-11-04 | $322.75M derived: sum of 2 quarters · filed 2026-08-05 | $468.28M 10-Q · filed 2025-11-04 | $599.82M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $163.35M 10-Q · filed 2026-08-05 | $308.89M 10-Q · filed 2026-08-05 | $440.42M derived: sum of 3 quarters · filed 2026-08-05 | $557.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $145.53M 10-Q · filed 2026-05-06 | $277.07M derived: sum of 2 quarters · filed 2026-05-06 | $394.15M derived: sum of 3 quarters · filed 2026-05-06 | $503.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $131.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $248.62M derived: sum of 2 quarters · filed 2026-02-26 | $357.95M derived: sum of 3 quarters · filed 2026-02-26 | $450.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $117.08M 10-Q · filed 2025-11-04 | $226.42M derived: sum of 2 quarters · filed 2025-11-04 | $319.18M 10-Q · filed 2025-11-04 | $412.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $109.33M 10-Q · filed 2025-08-05 | $202.09M 10-Q · filed 2025-08-05 | $295.49M derived: sum of 3 quarters · filed 2026-02-26 | $382.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $92.76M 10-Q · filed 2025-05-06 | $186.16M derived: sum of 2 quarters · filed 2026-02-26 | $272.90M derived: sum of 3 quarters · filed 2026-02-26 | $355.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $93.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $180.14M derived: sum of 2 quarters · filed 2026-02-26 | $262.63M derived: sum of 3 quarters · filed 2026-02-26 | $331.41M 10-K · filed 2026-02-26 |
| 2023-09-30 | $86.74M 10-Q · filed 2024-11-05 | $169.23M derived: sum of 2 quarters · filed 2024-11-05 | $238.01M 10-Q · filed 2024-11-05 | $317.56M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $82.49M 10-Q · filed 2024-08-06 | $151.27M 10-Q · filed 2024-08-06 | $230.81M derived: sum of 3 quarters · filed 2025-02-25 | $306.64M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $68.78M 10-Q · filed 2024-05-07 | $148.32M derived: sum of 2 quarters · filed 2025-02-25 | $224.15M derived: sum of 3 quarters · filed 2025-02-25 | $289.68M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $79.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $155.37M derived: sum of 2 quarters · filed 2025-02-25 | $220.90M derived: sum of 3 quarters · filed 2025-02-25 | $270.83M 10-K · filed 2025-02-25 |
| 2022-09-30 | $75.83M 10-Q · filed 2023-11-08 | $141.36M derived: sum of 2 quarters · filed 2023-11-08 | $191.28M 10-Q · filed 2023-11-08 | $238.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $65.53M 10-Q · filed 2023-08-07 | $115.45M 10-Q · filed 2023-08-07 | $162.61M derived: sum of 3 quarters · filed 2024-02-27 | $203.61M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $49.92M 10-Q · filed 2023-05-08 | $97.08M derived: sum of 2 quarters · filed 2024-02-27 | $138.07M derived: sum of 3 quarters · filed 2024-02-27 | $188.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $47.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $88.15M derived: sum of 2 quarters · filed 2024-02-27 | $138.11M derived: sum of 3 quarters · filed 2024-02-27 | $157.17M 10-K · filed 2024-02-27 |
| 2021-09-30 | $40.99M 10-Q · filed 2022-11-04 | $90.95M derived: sum of 2 quarters · filed 2022-11-04 | $110.01M 10-Q · filed 2022-11-04 | $114.03M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $49.96M 10-Q · filed 2022-08-05 | $69.02M 10-Q · filed 2022-08-05 | $73.03M derived: sum of 3 quarters · filed 2022-08-05 | $79.14M derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $19.06M 10-Q · filed 2022-05-09 | $23.07M derived: sum of 2 quarters · filed 2022-05-09 | $29.18M derived: sum of 3 quarters · filed 2022-05-09 | $32.05M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $4.02M 10-K · filed 2021-03-01 | $10.12M derived: sum of 2 quarters · filed 2021-11-04 | $12.99M derived: sum of 3 quarters · filed 2021-11-04 | $17.81M 10-K · filed 2023-02-27 |
| 2020-09-30 | $6.10M 10-Q · filed 2021-11-04 | $8.97M derived: sum of 2 quarters · filed 2021-11-04 | $13.80M 10-Q · filed 2021-11-04 | $53.52M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $2.87M 10-Q · filed 2021-08-09 | $7.69M 10-Q · filed 2021-08-09 | $47.42M derived: sum of 3 quarters · filed 2021-08-09 | $49.19M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $4.82M 10-Q · filed 2021-05-07 | $44.55M derived: sum of 2 quarters · filed 2021-05-07 | $46.32M derived: sum of 3 quarters · filed 2021-05-07 | $47.77M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $39.73M 10-K · filed 2021-03-01 | $41.50M derived: sum of 2 quarters · filed 2021-03-01 | $42.95M derived: sum of 3 quarters · filed 2021-03-01 | $48.84M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.77M 10-K · filed 2021-03-01 | $3.22M derived: sum of 2 quarters · filed 2021-03-01 | $9.11M 10-Q · filed 2020-11-06 | $11.84M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $1.45M 10-K · filed 2021-03-01 | $7.33M 10-Q · filed 2020-08-07 | $10.06M derived: sum of 3 quarters · filed 2021-03-01 | $11.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $5.89M 10-K · filed 2021-03-01 | $8.62M derived: sum of 2 quarters · filed 2021-03-01 | $10.07M derived: sum of 3 quarters · filed 2021-03-01 | $22.56M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $2.73M 10-K · filed 2020-03-13 | $4.18M derived: sum of 2 quarters · filed 2020-03-13 | $16.68M derived: sum of 3 quarters · filed 2020-03-13 | $20.65M 10-K · filed 2021-03-01 |
| 2018-09-30 | $1.45M 10-K · filed 2020-03-13 | $13.95M derived: sum of 2 quarters · filed 2020-03-13 | $17.92M 10-Q · filed 2019-11-08 | $21.81M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-06-30 | $12.49M 10-K · filed 2020-03-13 | $16.47M 10-Q · filed 2019-08-08 | $20.36M derived: sum of 3 quarters · filed 2020-03-13 | $29.12M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-03-31 | $3.98M 10-K · filed 2020-03-13 | $7.87M derived: sum of 2 quarters · filed 2020-03-13 | $16.63M derived: sum of 3 quarters · filed 2020-03-13 | $19.73M derived: sum of 4 quarters · filed 2020-03-13 |
| 2017-12-31 | $3.89M 10-K · filed 2019-03-14 | $12.65M derived: sum of 2 quarters · filed 2019-03-14 | $15.75M derived: sum of 3 quarters · filed 2019-03-14 | $25.19M 10-K · filed 2020-03-13 |
| 2017-09-30 | $8.76M 10-K · filed 2019-03-14 | $11.86M derived: sum of 2 quarters · filed 2019-03-14 | $21.30M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $3.10M 10-K · filed 2019-03-14 | $12.54M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $9.44M 10-K · filed 2019-03-14 | |||
| 2016-12-31 | $26.35M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |